...
首页> 外文期刊>Journal of cardiovascular pharmacology and therapeutics >High-dose atorvastatin reloading before percutaneous coronary intervention increased circulating endothelial progenitor cells and reduced inflammatory cytokine expression during the perioperative period
【24h】

High-dose atorvastatin reloading before percutaneous coronary intervention increased circulating endothelial progenitor cells and reduced inflammatory cytokine expression during the perioperative period

机译:经皮冠状动脉介入治疗前大剂量阿托伐他汀重装增加围手术期循环内皮祖细胞并降低炎性细胞因子表达

获取原文
获取原文并翻译 | 示例

摘要

Objective: We investigated atorvastatin reloading effects on endothelial progenitor cell (EPC) count and inflammatory cytokine expression after percutaneous coronary intervention (PCI) in patients with stable angina pectoris who had previously received long-term statin treatments. Methods: Patients with stable angina pectoris were treated with 80 mg atorvastatin 12 hours and 40 mg atorvastatin 2 hours before coronary angioplasty (n = 15) or preoperatively with 40 mg/d atorvastatin for 7 days (n = 15) or did not receive atorvastatin (n = 15). CD45-/133+/34+, CD45-/CD34+/kinase insert domain receptor (KDR)+, and CD45-/ CD144+/KDR+ EPCs in the peripheral blood were determined by flow cytometry 1 hour before as well as 1 hour, 6 hours, and 24 hours after PCI. Soluble intercellular adhesion molecule 1 (sICAM-1), hypersensitive C-reactive protein (hCRP), and troponin-I (TnI) serum concentrations were analyzed immediately prior to and 24 hours after PCI. Results: In the 40mg Atorvastatin and control groups, none of the analyzed EPC blood concentrations changed significantly from 1h before operation to 1h and 6 h postoperative values. In contrast, the number of circulating early differentiation stage EPCs CD45-/133+/34+ and CD45-/ CD34+/ KDR+ raised significantly from 1 h preoperative values (57.3±9.3; 57.3 ± 10.7) to 1 h postoperative (174.4 ± 11.4; 78.8±16.2), (p < 0.05)) and 6 h postoperative ((93±16.9; 99.7±11.9), (p < 0.05)) concentrations after coronary angioplasty in the 80mg Atorvastatin medication patients. In the control group, the sICAM-1 (174.55+38.91 vs 204.11+58.24) and hCRP (1.89 ± 1.93 vs 9.0 ± 11.1) serum concentrations at 24 hours after PCI were significantly elevated (P < .05) compared to preoperative values, whereas the increases in the 2 groups treated with atorvastatin were not significant. In addition, the rise in serum TnI concentration level from pre- to postoperative in the 80-mg (0.02±0.02 vs 0.09±0.08) and the 40-mg (0.01±0.03 vs 1.2 ± 2.59) reloading groups was less than that of the controls (0.01 ± 0.02 vs 1.75 ± 3.09) (p < 0.05). Conclusion: Our results suggested that high-dose atorvastatin application before PCI triggered early EPC circulation. Furthermore, postoperative inflammatory cytokine sICAM-1 as well as hCRP serum levels were reduced, while postinterventional myocardial injury marker TnI elevations were inversely correlated with statin reloadings.
机译:目的:我们研究了以前接受长期他汀类药物治疗的稳定型心绞痛患者经皮冠状动脉介入治疗(PCI)后,阿托伐他汀再加载对内皮祖细胞(EPC)计数和炎性细胞因子表达的影响。方法:稳定型心绞痛患者在冠状动脉血管成形术前(n = 15)2小时前用80 mg阿托伐他汀和40 mg阿托伐他汀治疗(n = 15),或术前用40 mg / d阿托伐他汀治疗7天(n = 15)或不接受阿托伐他汀(n = 15)。在1小时之前以及1小时,6时通过流式细胞仪测定外周血中的CD45- / 133 + / 34 +,CD45- / CD34 + /激酶插入域受体(KDR)+和CD45- / CD144 + / KDR + EPC小时和PCI之后的24小时。在PCI之前和之后24小时对可溶性细胞间粘附分子1(sICAM-1),超敏C反应蛋白(hCRP)和肌钙蛋白-I(TnI)血清浓度进行了分析。结果:在40mg阿托伐他汀和对照组中,从术前1h到术后1h和术后6h的EPC血药浓度均无明显变化。相反,循环早期分化期EPC CD45- / 133 + / 34 +和CD45- / CD34 + / KDR +的数量从术前1 h的值(57.3±9.3; 57.3±10.7)显着提高到术后1 h(174.4±11.4) ;在80mg阿托伐他汀药物治疗的患者中,在冠状动脉血管成形术后浓度(78.8±16.2),(p <0.05))和术后6 h((93±16.9; 99.7±11.9),(p <0.05))浓度。在对照组中,PCI后24小时的sICAM-1(174.55 + 38.91 vs 204.11 + 58.24)和hCRP(1.89±1.93 vs 9.0±11.1)血清浓度与术前相比明显升高(P <.05),而用阿托伐他汀治疗的两组的增加没有显着性。此外,在80 mg(0.02±0.02 vs 0.09±0.08)和40 mg(0.01±0.03 vs 1.2±2.59)再负荷组中,术前至术后血清TnI浓度水平的升高小于对照组。对照(0.01±0.02与1.75±3.09)(p <0.05)。结论:我们的研究结果表明,在PCI之前大剂量应用阿托伐他汀可引起早期EPC循环。此外,术后炎性细胞因子sICAM-1以及hCRP血清水平降低,而介入后心肌损伤标记物TnI升高与他汀类药物再加载呈负相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号